分子品質管理市場 製品(独立管理、機器別管理(PCR、DNAシーケンス))、用途(感染症診断)、分析物タイプ、エンドユーザー(病院、診断ラボ)、地域-2028年までの世界予測Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028 世界の分子品質管理市場は、予測期間中の年平均成長率6.6%で、2023年の2億米ドルから2028年には3億米ドルに達すると予測されている。この市場の成長は主に、ゲノムプロジェクトに対する政府資金の増加、個別化医... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー世界の分子品質管理市場は、予測期間中の年平均成長率6.6%で、2023年の2億米ドルから2028年には3億米ドルに達すると予測されている。この市場の成長は主に、ゲノムプロジェクトに対する政府資金の増加、個別化医薬品に対する需要の増加、シーケンス手順のコスト低下、感染症、癌、遺伝性疾患の有病率の増加によってもたらされる。しかし、品質管理プロセスにおける追加コストと病院や検査室における予算の制約、分子検査に対する不利な償還シナリオが、予測期間中にこの市場の成長を抑制すると予想される主な要因である。予測期間中、独立管理部門が市場で最大のシェアを占める 製品別では、分子品質管理市場は独立型コントロールと装置別コントロールに区分される。2022年の世界の分子品質管理市場では、独立型コントロール部門が最大のシェアを占めている。サードパーティの独立した品質管理装置の使用が増加していることが、このセグメントの大きなシェアの原因となっている。 単一分析物コントロールは、予測期間中、市場で最大のシェアを占めている。 分析物の種類によって、分子品質管理市場は単一分析物管理と複数分析物管理に分けられる。単一分析物コントロールは、2022年の分子品質管理市場で最大のシェアを占めた。病院でのシングルプレックスアッセイの大きな使用、交差反応性のリスクの低さなどの要因が、このセグメントの大きなシェアの原因となっている。 感染症診断分野が2022年の市場で最大シェアを占める 分子品質管理市場はアプリケーション別に、感染症診断、遺伝子検査、腫瘍学検査、その他のアプリケーション(神経疾患検査、DNAフィンガープリンティング、組織タイピング、微生物学、心血管疾患検査を含む)に分けられる。感染症診断セグメントは、2022年の分子品質管理世界市場で最大のシェアを占めた。感染症の流行の著しい増加が、このセグメントの大きなシェアの原因となっている。 診断検査部門は2022年に市場で最大のシェアを占めた。 エンドユーザー別では、分子品質管理市場は学術・研究機関、診断ラボ、IVDメーカー&CRO、病院、その他のエンドユーザー(在宅医療機関、血液銀行、老人ホーム、地域の公衆衛生研究所)に区分される。2022年の分子品質管理市場で最大のシェアを占めたのは診断ラボ部門であった。診断検査室で実施される臨床検査数の増加が、このセグメントの大きなシェアの原因となっている。 2022年の分子品質管理市場は北米が最大シェアを占める 地域別に見ると、分子品質管理市場は北米、欧州、アジア太平洋、中南米、中東・アフリカに区分される。北米は2022年に分子品質管理市場を支配した。この地域セグメントのシェアが大きいのは、主に米国とカナダで医療制度が発達していること、分子品質管理製品の大手メーカーが多数存在すること、北米で技術的に先進的な製品に容易にアクセスできることによる。 分子品質管理市場における主要参入企業のプロファイルの内訳: - 企業タイプ別:ティア1- 35%、ティア2- 45%、ティア3-20 - 役職別Cレベル幹部35%、取締役25%、その他40%。 - 地域別北米40%、欧州30%、アジア太平洋地域20%、中南米5%、中東・アフリカ5 分子品質管理市場の主要企業 分子品質管理市場に参入している主要企業は、Microbiologics, Inc.(米国)、Steck, Inc.(米国)、Bio-Rad Laboratories, Inc.(米国)、Anchor Molecular(米国)、Thermo Fisher Scientific, Inc.(米国)、Randox Laboratories Ltd.(英国)、LGC Limited(英国)、Microbiologics, Inc.(英国)、LGC Limited(英国)、Abbott Laboratories(米国)、Fortress Diagnostics(英国)、SERO AS(ノルウェー)、Anchor Molecular(米国)、Vircell S.L.(スペイン)、Ortho Clinical Diagnostics, Inc.(Ltd.(スイス)、Danaher Corporation(米国)、Microbix Biosystems Inc.(カナダ)、Molbio Diagnostics Pvt.(Ltd.(インド)、QuidelOrthoCorporation(米国)、Sun Diagnostics, LLC(米国)、Seegene Inc.(韓国)、ZeptoMetrix, LLC(米国)、Qnostics(英国)、Bio-Techne Corporation(米国)、Helena Laboratories Corporation(米国)、SpeeDx Pty.Ltd.(オーストラリア)、Maine Molecular Pty.(Ltd.(オーストラリア)、Maine Molecular Quality Controls, Inc.(米国)、Grifols, S.A.(スペイン)。 調査範囲 当レポートでは、分子品質管理市場を分析し、製品、分析対象物タイプ、用途、エンドユーザーなどの様々なセグメントに基づいて、市場規模と今後の成長可能性を推計することを目的としています。また、市場で入手可能な様々な分子品質管理製品の製品ポートフォリオマトリックスも掲載しています。また、同市場における主要企業の競合分析も行っており、企業プロフィール、サービス内容、主要市場戦略も掲載しています。 レポート購入の理由 本レポートは、既存企業だけでなく、新規参入企業や小規模企業にとっても、市場の動向を把握する上で有益であり、ひいては市場シェアを拡大する上で役立ちます。本レポートを購入される企業は、以下の戦略のいずれか、または任意の組み合わせを使用して、市場での地位を強化することができます。 本レポートは、以下のポイントに関する洞察を提供する: - 主な促進要因(第三者品質管理の採用拡大、ゲノミクスへの投資の増加、個別化医薬品への嗜好の高まり、外部品質評価サポートへの需要の高まり、感染症および癌の有病率の増加)、阻害要因(臨床検査室における高コストと予算制約、分子検査に対する不利な償還)、機会(複数分析項目の管理に対する需要の高まり、新興国における成長機会)、課題(規制枠組みの変化)の分析 - 製品開発/イノベーション:世界の分子品質管理市場における今後の動向、研究開発活動、新製品発売に関する詳細な洞察 - 市場開発:製品、分析物の種類、用途、エンドユーザー別の有利な新興市場に関する包括的情報。 - 市場の多様化:世界の分子品質管理市場における新サービスやサービスの強化、成長地域、最近の開発、投資に関する詳細な情報。 - 競合評価:世界の分子品質管理市場における主要企業の市場シェア、成長戦略、製品提供、企業評価象限、能力を詳細に評価します。また本レポートは、関係者が分子品質管理市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。 目次1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 24 1.3 MARKET SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 26 TABLE 1 STANDARD CURRENCY CONVERSION RATES 26 1.5 STUDY LIMITATIONS 27 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 27 1.8 RECESSION IMPACT 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 FIGURE 1 RESEARCH DESIGN 29 2.2 RESEARCH DESIGN 29 2.2.1 SECONDARY RESEARCH 29 2.2.1.1 Key data from secondary sources 30 2.2.2 PRIMARY RESEARCH 31 FIGURE 2 PRIMARY SOURCES 31 2.2.2.1 Key data from primary sources 32 FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS 33 2.2.2.2 Breakdown of primaries 33 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.3 MARKET SIZE ESTIMATION 34 FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35 FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS 36 FIGURE 7 MARKET SIZE ESTIMATION: PARENT MARKET 37 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38 FIGURE 9 MOLECULAR QUALITY CONTROLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41 FIGURE 10 DATA TRIANGULATION METHODOLOGY 41 2.5 MARKET SHARE ANALYSIS 42 2.6 STUDY ASSUMPTIONS 42 2.7 RISK ASSESSMENT 42 TABLE 2 MOLECULAR QUALITY CONTROLS MARKET: RISK ASSESSMENT ANALYSIS 42 2.8 MARKET LIMITATIONS 43 2.8.1 METHODOLOGY-RELATED LIMITATIONS 43 2.8.2 SCOPE-RELATED LIMITATIONS 43 2.9 RECESSION IMPACT ANALYSIS 43 3 EXECUTIVE SUMMARY 45 FIGURE 11 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 45 FIGURE 12 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2023 VS. 2028 (USD MILLION) 46 FIGURE 13 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46 FIGURE 14 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47 FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MOLECULAR QUALITY CONTROLS MARKET 48 4 PREMIUM INSIGHTS 49 4.1 MOLECULAR QUALITY CONTROLS MARKET OVERVIEW 49 FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET 49 4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 50 FIGURE 17 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50 4.3 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION AND COUNTRY 51 FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT IN JAPAN ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 51 4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHICAL MIX 52 FIGURE 19 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 52 4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS 53 FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 FIGURE 21 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 5.1.1 DRIVERS 55 5.1.1.1 Rising number of accredited clinical laboratories 55 FIGURE 22 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 55 5.1.1.2 Growing adoption of third-party quality controls 56 TABLE 3 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY COMPANIES 56 5.1.1.3 Increasing investments in genomics 57 TABLE 4 GOVERNMENT FUNDING INITIATIVES FOR GENOMICS RESEARCH (2019−2022) 57 5.1.1.4 Growing preference for personalized medicine 58 TABLE 5 US: NUMBER OF PERSONALIZED MEDICINES AVAILABLE (2008–2020) 59 FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES (2015–2022) 59 FIGURE 24 COST OF SEQUENCING PROCEDURES (2016−2021) 60 5.1.1.5 Increasing prevalence of infectious diseases and cancer 60 FIGURE 25 GLOBAL CANCER INCIDENCE, 2018–2040 (MILLION) 61 5.1.1.6 Rising demand for external quality assessment support 62 5.1.2 RESTRAINTS 62 5.1.2.1 Budgetary constraints in clinical laboratories 62 5.1.2.2 Unfavorable reimbursements for molecular tests 63 5.1.3 OPPORTUNITIES 63 5.1.3.1 Rising demand for multi-analyte controls 63 5.1.3.2 Growth opportunities in emerging markets 64 5.1.4 CHALLENGES 64 5.1.4.1 Stringent regulatory requirements for IVD products 64 5.2 INDUSTRY TRENDS 65 5.2.1 LYOPHILIZED/FREEZE-DRIED CONTROLS 65 TABLE 6 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY COMPANIES 65 5.3 PRICING ANALYSIS 66 TABLE 7 PRICE RANGE FOR MOLECULAR QUALITY CONTROLS, BY TYPE (2022) 66 5.4 VALUE CHAIN ANALYSIS 66 FIGURE 26 VALUE CHAIN ANALYSIS 67 5.5 SUPPLY CHAIN ANALYSIS 67 FIGURE 27 SUPPLY CHAIN ANALYSIS 68 5.6 ECOSYSTEM ANALYSIS 68 FIGURE 28 MOLECULAR QUALITY CONTROLS MARKET: ECOSYSTEM MARKET MAP 69 5.7 PORTER’S FIVE FORCES ANALYSIS 69 TABLE 8 MOLECULAR QUALITY CONTROLS MARKET: PORTER’S FIVE FORCES ANALYSIS 69 5.7.1 THREAT OF NEW ENTRANTS 70 5.7.2 THREAT OF SUBSTITUTES 70 5.7.3 BARGAINING POWER OF BUYERS 70 5.7.4 BARGAINING POWER OF SUPPLIERS 70 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 71 5.8 TRADE ANALYSIS 71 5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 71 5.8.1.1 Import data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71 5.8.1.2 Export data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71 5.9 TARIFF AND REGULATORY ANALYSIS 72 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.9.2 REGULATORY ANALYSIS 72 5.9.2.1 North America 72 5.9.2.1.1 US 72 TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 73 TABLE 11 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL 73 TABLE 12 US: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 73 5.9.2.1.2 Canada 74 TABLE 13 CANADA: CLASSIFICATION OF IVD PRODUCTS 74 TABLE 14 CANADA: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 74 5.9.2.2 Europe 75 TABLE 15 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 75 5.9.2.3 Asia Pacific 75 5.9.2.3.1 Japan 75 5.9.2.3.2 China 76 5.9.2.3.3 India 76 5.10 PATENT ANALYSIS 76 5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 76 FIGURE 29 MOLECULAR QUALITY CONTROLS MARKET: TOP PATENT OWNERS AND APPLICANTS (JANUARY 2011–JUNE 2023) 77 FIGURE 30 MOLECULAR QUALITY CONTROLS MARKET: TOP APPLICANT JURISDICTIONS (JANUARY 2011–JUNE 2023) 78 5.10.2 PATENT PUBLICATION TRENDS 78 FIGURE 31 MOLECULAR QUALITY CONTROLS MARKET: PATENT ANALYSIS (JANUARY 2011–FEBRUARY 2023) 78 TABLE 16 MOLECULAR QUALITY CONTROLS MARKET: LIST OF PATENTS/PATENT APPLICATIONS (2020–2023) 79 5.11 KEY CONFERENCES AND EVENTS 80 TABLE 17 MOLECULAR QUALITY CONTROLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 80 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 81 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 81 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS 81 TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS (%) 81 5.12.2 BUYING CRITERIA 82 FIGURE 33 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82 TABLE 19 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82 5.13 TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 83 FIGURE 34 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHIFT 83 6 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 84 6.1 INTRODUCTION 85 TABLE 20 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS 85 TABLE 21 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 86 6.2 INDEPENDENT CONTROLS 86 6.2.1 MINIMIZED LOT CROSSOVERS FOR LABORATORIES AND LOW OPERATION COSTS TO DRIVE MARKET 86 TABLE 22 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 86 TABLE 23 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 6.3 INSTRUMENT-SPECIFIC CONTROLS 88 TABLE 24 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 88 TABLE 25 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89 TABLE 26 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 89 6.3.1 POLYMERASE CHAIN REACTION 90 6.3.1.1 Rising applications in proteomics and genomics to propel market 90 TABLE 27 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 91 6.3.2 DNA SEQUENCING AND NGS 91 6.3.2.1 Increasing advancements in sequencing technologies to drive market 91 TABLE 28 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2028 (USD MILLION) 92 6.3.3 OTHER TECHNOLOGIES 92 TABLE 29 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 93 7 MOLECULAR QUALITY CONTROL MARKET, BY ANALYTE TYPE 94 7.1 INTRODUCTION 95 TABLE 30 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 95 7.2 SINGLE-ANALYTE CONTROLS 95 7.2.1 RISING ADOPTION OF SINGLEPLEX ASSAYS IN HOSPITALS TO SUPPORT MARKET GROWTH 95 TABLE 31 SINGLE-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 96 TABLE 32 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96 7.3 MULTI-ANALYTE CONTROLS 97 7.3.1 GROWING PREFERENCE FOR COST-EFFECTIVE CONTROLS TO DRIVE MARKET 97 TABLE 33 MULTI-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 97 TABLE 34 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98 8 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION 99 8.1 INTRODUCTION 100 TABLE 35 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100 8.2 INFECTIOUS DISEASE DIAGNOSTICS 100 8.2.1 RISING INCIDENCE OF INFLUENZA, TB, AND HIV TO DRIVE MARKET 100 TABLE 36 NUMBER OF COVID-19 CASES, BY COUNTRY (FEBRUARY 2023) 101 TABLE 37 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 102 8.3 ONCOLOGY TESTING 103 8.3.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO PROPEL MARKET 103 TABLE 38 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 104 TABLE 39 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 105 8.4 GENETIC TESTING 105 8.4.1 ABILITY TO DIAGNOSE RARE DISEASES TO SUPPORT MARKET GROWTH 105 TABLE 40 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 106 8.5 OTHER APPLICATIONS 106 TABLE 41 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107 9 MOLECULAR QUALITY CONTROLS MARKET, BY END USER 108 9.1 INTRODUCTION 109 TABLE 42 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 109 9.2 DIAGNOSTIC LABORATORIES 109 9.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO DRIVE MARKET 109 TABLE 43 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 111 9.3 HOSPITALS 111 9.3.1 ABILITY TO CONDUCT LARGE VOLUME OF DIAGNOSTIC PROCEDURES TO PROPEL MARKET 111 TABLE 44 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 113 9.4 IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS 113 9.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH 113 TABLE 45 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 114 9.5 ACADEMIC & RESEARCH INSTITUTES 114 9.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET 114 TABLE 46 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 115 9.6 OTHER END USERS 115 TABLE 47 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 116 10 MOLECULAR QUALITY CONTROLS MARKET, BY REGION 117 10.1 INTRODUCTION 118 TABLE 48 MOLECULAR QUALITY CONTROLS MARKET, BY REGION, 2021–2028 (USD MILLION) 118 10.2 NORTH AMERICA 118 FIGURE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 119 TABLE 49 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119 TABLE 50 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120 TABLE 51 NORTH AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120 TABLE 52 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 120 TABLE 53 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121 TABLE 54 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 121 10.2.1 US 121 10.2.1.1 Growing number of accredited clinical laboratories to drive market 121 FIGURE 36 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 122 TABLE 55 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123 TABLE 56 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123 TABLE 57 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 123 TABLE 58 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124 TABLE 59 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 124 10.2.2 CANADA 124 10.2.2.1 Rising funding investments for genomic research to propel market 124 TABLE 60 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125 TABLE 61 CANADA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126 TABLE 62 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 126 TABLE 63 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126 TABLE 64 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 127 10.2.3 NORTH AMERICA: RECESSION IMPACT 127 10.3 EUROPE 127 TABLE 65 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 66 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128 TABLE 67 EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129 TABLE 68 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 129 TABLE 69 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129 TABLE 70 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.3.1 GERMANY 130 10.3.1.1 Rising volume of diagnostic tests in clinical settings to drive market 130 TABLE 71 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 130 TABLE 72 GERMANY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131 TABLE 73 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 131 TABLE 74 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131 TABLE 75 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 132 10.3.2 UK 132 10.3.2.1 Growth in life sciences industry to propel market 132 TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133 TABLE 77 UK: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133 TABLE 78 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 133 TABLE 79 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134 TABLE 80 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 134 10.3.3 FRANCE 134 10.3.3.1 Rising prevalence of cancer and endocrine disorders to support market growth 134 TABLE 81 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 135 TABLE 82 FRANCE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135 TABLE 83 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 135 TABLE 84 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136 TABLE 85 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 136 10.3.4 ITALY 136 10.3.4.1 Rising incidence of age-associated chronic ailments to support market growth 136 TABLE 86 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137 TABLE 87 ITALY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137 TABLE 88 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 137 TABLE 89 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138 TABLE 90 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 138 10.3.5 SPAIN 138 10.3.5.1 Increasing demand for prenatal and genetic testing to support market growth 138 TABLE 91 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139 TABLE 92 SPAIN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139 TABLE 93 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 140 TABLE 94 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140 TABLE 95 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 140 10.3.6 RUSSIA 141 10.3.6.1 Growing acceptance of molecular diagnostics-based personalized medicine to propel market 141 TABLE 96 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141 TABLE 97 RUSSIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141 TABLE 98 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 142 TABLE 99 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142 TABLE 100 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 142 10.3.7 REST OF EUROPE 143 TABLE 101 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143 TABLE 102 REST OF EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143 TABLE 103 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 144 TABLE 104 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144 TABLE 105 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 144 10.3.8 EUROPE: RECESSION IMPACT 145 10.4 ASIA PACIFIC 145 FIGURE 37 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 146 TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147 TABLE 107 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147 TABLE 108 ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 147 TABLE 109 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 148 TABLE 110 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148 TABLE 111 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 148 10.4.1 JAPAN 149 10.4.1.1 Established healthcare system and rising demand for high-quality IVD tests to drive market 149 TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 149 TABLE 113 JAPAN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149 TABLE 114 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 150 TABLE 115 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150 TABLE 116 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 150 10.4.2 CHINA 151 10.4.2.1 Rising R&D investments for advanced molecular tests to drive market 151 TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151 TABLE 118 CHINA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152 TABLE 119 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 152 TABLE 120 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152 TABLE 121 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 153 10.4.3 INDIA 153 10.4.3.1 Rising need to secure NABL accreditations to support market growth 153 FIGURE 38 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS (2012–2020) 154 TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154 TABLE 123 INDIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 155 TABLE 125 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155 TABLE 126 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 156 10.4.4 AUSTRALIA 156 10.4.4.1 High prevalence of infectious diseases to fuel market 156 TABLE 127 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156 TABLE 128 AUSTRALIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157 TABLE 129 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 157 TABLE 130 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157 TABLE 131 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 158 10.4.5 REST OF ASIA PACIFIC 158 TABLE 132 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158 TABLE 133 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159 TABLE 134 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 159 TABLE 135 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159 TABLE 136 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 160 10.4.6 ASIA PACIFIC: RECESSION IMPACT 160 10.5 LATIN AMERICA 160 TABLE 137 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161 TABLE 138 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161 TABLE 139 LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161 TABLE 140 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 162 TABLE 141 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162 TABLE 142 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, ‘ 2021–2028 (USD MILLION) 162 10.5.1 BRAZIL 163 10.5.1.1 Improving healthcare infrastructure to support market growth 163 TABLE 143 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163 TABLE 144 BRAZIL: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163 TABLE 145 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 164 TABLE 146 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164 TABLE 147 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 164 10.5.2 MEXICO 165 10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth 165 TABLE 148 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 165 TABLE 149 MEXICO: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165 TABLE 150 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 166 TABLE 151 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166 TABLE 152 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 166 10.5.3 REST OF LATIN AMERICA 167 TABLE 153 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167 TABLE 154 REST OF LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167 TABLE 155 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 167 TABLE 156 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168 TABLE 157 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 168 10.5.4 LATIN AMERICA: RECESSION IMPACT 168 10.6 MIDDLE EAST & AFRICA 169 10.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 169 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 169 TABLE 158 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169 TABLE 159 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 170 TABLE 160 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 170 TABLE 161 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170 TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 171 11 COMPETITIVE LANDSCAPE 172 11.1 OVERVIEW 172 11.2 STRATEGIES ADOPTED BY KEY PLAYERS 173 11.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 174 FIGURE 39 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS 174 11.4 MARKET SHARE ANALYSIS 175 FIGURE 40 MOLECULAR QUALITY CONTROLS MARKET SHARE ANALYSIS, BY KEY PLAYER (2022) 175 TABLE 163 MOLECULAR QUALITY CONTROLS MARKET: INTENSITY OF COMPETITIVE RIVALRY 176 11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 177 11.5.1 STARS 177 11.5.2 EMERGING LEADERS 177 11.5.3 PERVASIVE PLAYERS 178 11.5.4 PARTICIPANTS 178 FIGURE 41 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 178 11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 179 11.6.1 PROGRESSIVE COMPANIES 179 11.6.2 STARTING BLOCKS 179 11.6.3 RESPONSIVE COMPANIES 179 11.6.4 DYNAMIC COMPANIES 179 FIGURE 42 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 180 11.7 COMPANY FOOTPRINT ANALYSIS 180 TABLE 164 MOLECULAR QUALITY CONTROLS MARKET: COMPANY FOOTPRINT ANALYSIS 181 TABLE 165 MOLECULAR QUALITY CONTROLS MARKET: ANALYTE TYPE FOOTPRINT ANALYSIS 182 TABLE 166 MOLECULAR QUALITY CONTROLS MARKET: APPLICATION FOOTPRINT ANALYSIS 183 TABLE 167 MOLECULAR QUALITY CONTROLS MARKET: REGIONAL FOOTPRINT ANALYSIS 184 TABLE 168 MOLECULAR QUALITY CONTROLS MARKET: END USER FOOTPRINT ANALYSIS 185 11.8 COMPETITIVE SITUATION AND TRENDS 186 11.8.1 PRODUCT LAUNCHES & APPROVALS 186 TABLE 169 PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023) 186 11.8.2 DEALS 187 TABLE 170 DEALS (JANUARY 2020–JUNE 2023) 187 11.8.3 OTHER DEVELOPMENTS 187 TABLE 171 OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023) 188 12 COMPANY PROFILES 189 12.1 KEY PLAYERS 189 (Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)* 12.1.1 LGC LIMITED 189 TABLE 172 LGC LIMITED: BUSINESS OVERVIEW 189 FIGURE 43 LCG LIMITED: COMPANY SNAPSHOT (2022) 190 12.1.2 THERMO FISHER SCIENTIFIC, INC. 198 TABLE 173 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 198 FIGURE 44 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 199 12.1.3 BIO-RAD LABORATORIES, INC. 205 TABLE 174 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 205 FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 206 12.1.4 MICROBIOLOGICS, INC. 209 TABLE 175 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 209 12.1.5 ABBOTT LABORATORIES 214 TABLE 176 ABBOTT LABORATORIES: BUSINESS OVERVIEW 214 FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 215 12.1.6 F. HOFFMANN-LA ROCHE LTD. 218 TABLE 177 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 218 FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 219 12.1.7 ZEPTOMETRIX, LLC 221 TABLE 178 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW 221 12.1.8 QUIDELORTHO CORPORATION 226 TABLE 179 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 226 FIGURE 48 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 227 12.1.9 QNOSTICS 229 TABLE 180 QNOSTICS: BUSINESS OVERVIEW 229 12.1.10 MAINE MOLECULAR QUALITY CONTROLS, INC. 232 TABLE 181 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW 232 12.1.11 RANDOX LABORATORIES LTD. 235 TABLE 182 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 235 12.1.12 DANAHER CORPORATION 238 TABLE 183 DANAHER CORPORATION: BUSINESS OVERVIEW 238 FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 239 12.1.13 BIO-TECHNE CORPORATION 241 TABLE 184 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 241 FIGURE 50 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 242 12.1.14 FORTRESS DIAGNOSTICS 244 TABLE 185 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW 244 12.1.15 MICROBIX BIOSYSTEMS 246 TABLE 186 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW 246 FIGURE 51 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2022) 247 12.1.16 GRIFOLS, S.A. 251 TABLE 187 GRIFOLS, S.A.: BUSINESS OVERVIEW 251 FIGURE 52 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022) 252 12.1.17 ANCHOR MOLECULAR 254 TABLE 188 ANCHOR MOLECULAR: BUSINESS OVERVIEW 254 12.1.18 SPEEDX PTY. LTD. 255 TABLE 189 SPEEDX PTY. LTD.: BUSINESS OVERVIEW 255 12.1.19 SEEGENE INC. 257 TABLE 190 SEEGENE INC.: BUSINESS OVERVIEW 257 FIGURE 53 SEEGENE INC: COMPANY SNAPSHOT (2022) 258 12.1.20 HELENA LABORATORIES CORPORATION 262 TABLE 191 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW 262 12.2 OTHER PLAYERS 265 12.2.1 SERO AS 265 TABLE 192 SERO AS: BUSINESS OVERVIEW 265 12.2.2 VIRCELL, S.L. 267 TABLE 193 VIRCELL, S.L.: BUSINESS OVERVIEW 267 12.2.3 STRECK LLC 269 TABLE 194 STRECK LLC.: BUSINESS OVERVIEW 269 12.2.4 SUN DIAGNOSTICS, LLC 271 TABLE 195 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW 271 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 272 TABLE 196 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW 272 *Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 13 APPENDIX 273 13.1 DISCUSSION GUIDE 273 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277 13.3 CUSTOMIZATION OPTIONS 279 13.4 RELATED REPORTS 279 13.5 AUTHOR DETAILS 280
SummaryThe global molecular quality controls market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 6.6% during the forecast period. Growth in this market is primarily driven by the increasing government funding for genomic projects, increasing demand for personalized medicines and declining costs of sequencing procedures, and increasing prevalence of infectious diseases, cancer, and genetic diseases. However, the additional costs involved in the quality control process and budget constraints in hospitals and laboratories, and the unfavorable reimbursement scenario for molecular tests are the major factors that are expected to restrain the growth of this market during the forecast period. Table of Contents1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 24 1.3 MARKET SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 26 TABLE 1 STANDARD CURRENCY CONVERSION RATES 26 1.5 STUDY LIMITATIONS 27 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 27 1.8 RECESSION IMPACT 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 FIGURE 1 RESEARCH DESIGN 29 2.2 RESEARCH DESIGN 29 2.2.1 SECONDARY RESEARCH 29 2.2.1.1 Key data from secondary sources 30 2.2.2 PRIMARY RESEARCH 31 FIGURE 2 PRIMARY SOURCES 31 2.2.2.1 Key data from primary sources 32 FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS 33 2.2.2.2 Breakdown of primaries 33 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.3 MARKET SIZE ESTIMATION 34 FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35 FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS 36 FIGURE 7 MARKET SIZE ESTIMATION: PARENT MARKET 37 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38 FIGURE 9 MOLECULAR QUALITY CONTROLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41 FIGURE 10 DATA TRIANGULATION METHODOLOGY 41 2.5 MARKET SHARE ANALYSIS 42 2.6 STUDY ASSUMPTIONS 42 2.7 RISK ASSESSMENT 42 TABLE 2 MOLECULAR QUALITY CONTROLS MARKET: RISK ASSESSMENT ANALYSIS 42 2.8 MARKET LIMITATIONS 43 2.8.1 METHODOLOGY-RELATED LIMITATIONS 43 2.8.2 SCOPE-RELATED LIMITATIONS 43 2.9 RECESSION IMPACT ANALYSIS 43 3 EXECUTIVE SUMMARY 45 FIGURE 11 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 45 FIGURE 12 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2023 VS. 2028 (USD MILLION) 46 FIGURE 13 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46 FIGURE 14 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47 FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MOLECULAR QUALITY CONTROLS MARKET 48 4 PREMIUM INSIGHTS 49 4.1 MOLECULAR QUALITY CONTROLS MARKET OVERVIEW 49 FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET 49 4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 50 FIGURE 17 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50 4.3 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION AND COUNTRY 51 FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT IN JAPAN ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 51 4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHICAL MIX 52 FIGURE 19 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 52 4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS 53 FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 FIGURE 21 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 5.1.1 DRIVERS 55 5.1.1.1 Rising number of accredited clinical laboratories 55 FIGURE 22 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 55 5.1.1.2 Growing adoption of third-party quality controls 56 TABLE 3 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY COMPANIES 56 5.1.1.3 Increasing investments in genomics 57 TABLE 4 GOVERNMENT FUNDING INITIATIVES FOR GENOMICS RESEARCH (2019−2022) 57 5.1.1.4 Growing preference for personalized medicine 58 TABLE 5 US: NUMBER OF PERSONALIZED MEDICINES AVAILABLE (2008–2020) 59 FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES (2015–2022) 59 FIGURE 24 COST OF SEQUENCING PROCEDURES (2016−2021) 60 5.1.1.5 Increasing prevalence of infectious diseases and cancer 60 FIGURE 25 GLOBAL CANCER INCIDENCE, 2018–2040 (MILLION) 61 5.1.1.6 Rising demand for external quality assessment support 62 5.1.2 RESTRAINTS 62 5.1.2.1 Budgetary constraints in clinical laboratories 62 5.1.2.2 Unfavorable reimbursements for molecular tests 63 5.1.3 OPPORTUNITIES 63 5.1.3.1 Rising demand for multi-analyte controls 63 5.1.3.2 Growth opportunities in emerging markets 64 5.1.4 CHALLENGES 64 5.1.4.1 Stringent regulatory requirements for IVD products 64 5.2 INDUSTRY TRENDS 65 5.2.1 LYOPHILIZED/FREEZE-DRIED CONTROLS 65 TABLE 6 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY COMPANIES 65 5.3 PRICING ANALYSIS 66 TABLE 7 PRICE RANGE FOR MOLECULAR QUALITY CONTROLS, BY TYPE (2022) 66 5.4 VALUE CHAIN ANALYSIS 66 FIGURE 26 VALUE CHAIN ANALYSIS 67 5.5 SUPPLY CHAIN ANALYSIS 67 FIGURE 27 SUPPLY CHAIN ANALYSIS 68 5.6 ECOSYSTEM ANALYSIS 68 FIGURE 28 MOLECULAR QUALITY CONTROLS MARKET: ECOSYSTEM MARKET MAP 69 5.7 PORTER’S FIVE FORCES ANALYSIS 69 TABLE 8 MOLECULAR QUALITY CONTROLS MARKET: PORTER’S FIVE FORCES ANALYSIS 69 5.7.1 THREAT OF NEW ENTRANTS 70 5.7.2 THREAT OF SUBSTITUTES 70 5.7.3 BARGAINING POWER OF BUYERS 70 5.7.4 BARGAINING POWER OF SUPPLIERS 70 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 71 5.8 TRADE ANALYSIS 71 5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 71 5.8.1.1 Import data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71 5.8.1.2 Export data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71 5.9 TARIFF AND REGULATORY ANALYSIS 72 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.9.2 REGULATORY ANALYSIS 72 5.9.2.1 North America 72 5.9.2.1.1 US 72 TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 73 TABLE 11 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL 73 TABLE 12 US: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 73 5.9.2.1.2 Canada 74 TABLE 13 CANADA: CLASSIFICATION OF IVD PRODUCTS 74 TABLE 14 CANADA: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 74 5.9.2.2 Europe 75 TABLE 15 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 75 5.9.2.3 Asia Pacific 75 5.9.2.3.1 Japan 75 5.9.2.3.2 China 76 5.9.2.3.3 India 76 5.10 PATENT ANALYSIS 76 5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 76 FIGURE 29 MOLECULAR QUALITY CONTROLS MARKET: TOP PATENT OWNERS AND APPLICANTS (JANUARY 2011–JUNE 2023) 77 FIGURE 30 MOLECULAR QUALITY CONTROLS MARKET: TOP APPLICANT JURISDICTIONS (JANUARY 2011–JUNE 2023) 78 5.10.2 PATENT PUBLICATION TRENDS 78 FIGURE 31 MOLECULAR QUALITY CONTROLS MARKET: PATENT ANALYSIS (JANUARY 2011–FEBRUARY 2023) 78 TABLE 16 MOLECULAR QUALITY CONTROLS MARKET: LIST OF PATENTS/PATENT APPLICATIONS (2020–2023) 79 5.11 KEY CONFERENCES AND EVENTS 80 TABLE 17 MOLECULAR QUALITY CONTROLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 80 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 81 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 81 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS 81 TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS (%) 81 5.12.2 BUYING CRITERIA 82 FIGURE 33 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82 TABLE 19 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82 5.13 TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 83 FIGURE 34 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHIFT 83 6 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 84 6.1 INTRODUCTION 85 TABLE 20 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS 85 TABLE 21 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 86 6.2 INDEPENDENT CONTROLS 86 6.2.1 MINIMIZED LOT CROSSOVERS FOR LABORATORIES AND LOW OPERATION COSTS TO DRIVE MARKET 86 TABLE 22 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 86 TABLE 23 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 6.3 INSTRUMENT-SPECIFIC CONTROLS 88 TABLE 24 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 88 TABLE 25 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89 TABLE 26 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 89 6.3.1 POLYMERASE CHAIN REACTION 90 6.3.1.1 Rising applications in proteomics and genomics to propel market 90 TABLE 27 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 91 6.3.2 DNA SEQUENCING AND NGS 91 6.3.2.1 Increasing advancements in sequencing technologies to drive market 91 TABLE 28 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2028 (USD MILLION) 92 6.3.3 OTHER TECHNOLOGIES 92 TABLE 29 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 93 7 MOLECULAR QUALITY CONTROL MARKET, BY ANALYTE TYPE 94 7.1 INTRODUCTION 95 TABLE 30 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 95 7.2 SINGLE-ANALYTE CONTROLS 95 7.2.1 RISING ADOPTION OF SINGLEPLEX ASSAYS IN HOSPITALS TO SUPPORT MARKET GROWTH 95 TABLE 31 SINGLE-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 96 TABLE 32 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96 7.3 MULTI-ANALYTE CONTROLS 97 7.3.1 GROWING PREFERENCE FOR COST-EFFECTIVE CONTROLS TO DRIVE MARKET 97 TABLE 33 MULTI-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 97 TABLE 34 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98 8 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION 99 8.1 INTRODUCTION 100 TABLE 35 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100 8.2 INFECTIOUS DISEASE DIAGNOSTICS 100 8.2.1 RISING INCIDENCE OF INFLUENZA, TB, AND HIV TO DRIVE MARKET 100 TABLE 36 NUMBER OF COVID-19 CASES, BY COUNTRY (FEBRUARY 2023) 101 TABLE 37 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 102 8.3 ONCOLOGY TESTING 103 8.3.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO PROPEL MARKET 103 TABLE 38 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 104 TABLE 39 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 105 8.4 GENETIC TESTING 105 8.4.1 ABILITY TO DIAGNOSE RARE DISEASES TO SUPPORT MARKET GROWTH 105 TABLE 40 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 106 8.5 OTHER APPLICATIONS 106 TABLE 41 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107 9 MOLECULAR QUALITY CONTROLS MARKET, BY END USER 108 9.1 INTRODUCTION 109 TABLE 42 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 109 9.2 DIAGNOSTIC LABORATORIES 109 9.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO DRIVE MARKET 109 TABLE 43 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 111 9.3 HOSPITALS 111 9.3.1 ABILITY TO CONDUCT LARGE VOLUME OF DIAGNOSTIC PROCEDURES TO PROPEL MARKET 111 TABLE 44 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 113 9.4 IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS 113 9.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH 113 TABLE 45 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 114 9.5 ACADEMIC & RESEARCH INSTITUTES 114 9.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET 114 TABLE 46 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 115 9.6 OTHER END USERS 115 TABLE 47 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 116 10 MOLECULAR QUALITY CONTROLS MARKET, BY REGION 117 10.1 INTRODUCTION 118 TABLE 48 MOLECULAR QUALITY CONTROLS MARKET, BY REGION, 2021–2028 (USD MILLION) 118 10.2 NORTH AMERICA 118 FIGURE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 119 TABLE 49 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119 TABLE 50 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120 TABLE 51 NORTH AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120 TABLE 52 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 120 TABLE 53 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121 TABLE 54 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 121 10.2.1 US 121 10.2.1.1 Growing number of accredited clinical laboratories to drive market 121 FIGURE 36 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 122 TABLE 55 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123 TABLE 56 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123 TABLE 57 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 123 TABLE 58 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124 TABLE 59 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 124 10.2.2 CANADA 124 10.2.2.1 Rising funding investments for genomic research to propel market 124 TABLE 60 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125 TABLE 61 CANADA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126 TABLE 62 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 126 TABLE 63 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126 TABLE 64 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 127 10.2.3 NORTH AMERICA: RECESSION IMPACT 127 10.3 EUROPE 127 TABLE 65 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 66 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128 TABLE 67 EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129 TABLE 68 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 129 TABLE 69 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129 TABLE 70 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.3.1 GERMANY 130 10.3.1.1 Rising volume of diagnostic tests in clinical settings to drive market 130 TABLE 71 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 130 TABLE 72 GERMANY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131 TABLE 73 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 131 TABLE 74 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131 TABLE 75 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 132 10.3.2 UK 132 10.3.2.1 Growth in life sciences industry to propel market 132 TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133 TABLE 77 UK: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133 TABLE 78 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 133 TABLE 79 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134 TABLE 80 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 134 10.3.3 FRANCE 134 10.3.3.1 Rising prevalence of cancer and endocrine disorders to support market growth 134 TABLE 81 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 135 TABLE 82 FRANCE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135 TABLE 83 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 135 TABLE 84 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136 TABLE 85 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 136 10.3.4 ITALY 136 10.3.4.1 Rising incidence of age-associated chronic ailments to support market growth 136 TABLE 86 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137 TABLE 87 ITALY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137 TABLE 88 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 137 TABLE 89 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138 TABLE 90 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 138 10.3.5 SPAIN 138 10.3.5.1 Increasing demand for prenatal and genetic testing to support market growth 138 TABLE 91 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139 TABLE 92 SPAIN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139 TABLE 93 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 140 TABLE 94 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140 TABLE 95 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 140 10.3.6 RUSSIA 141 10.3.6.1 Growing acceptance of molecular diagnostics-based personalized medicine to propel market 141 TABLE 96 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141 TABLE 97 RUSSIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141 TABLE 98 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 142 TABLE 99 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142 TABLE 100 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 142 10.3.7 REST OF EUROPE 143 TABLE 101 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143 TABLE 102 REST OF EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143 TABLE 103 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 144 TABLE 104 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144 TABLE 105 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 144 10.3.8 EUROPE: RECESSION IMPACT 145 10.4 ASIA PACIFIC 145 FIGURE 37 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 146 TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147 TABLE 107 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147 TABLE 108 ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 147 TABLE 109 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 148 TABLE 110 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148 TABLE 111 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 148 10.4.1 JAPAN 149 10.4.1.1 Established healthcare system and rising demand for high-quality IVD tests to drive market 149 TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 149 TABLE 113 JAPAN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149 TABLE 114 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 150 TABLE 115 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150 TABLE 116 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 150 10.4.2 CHINA 151 10.4.2.1 Rising R&D investments for advanced molecular tests to drive market 151 TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151 TABLE 118 CHINA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152 TABLE 119 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 152 TABLE 120 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152 TABLE 121 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 153 10.4.3 INDIA 153 10.4.3.1 Rising need to secure NABL accreditations to support market growth 153 FIGURE 38 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS (2012–2020) 154 TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154 TABLE 123 INDIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 155 TABLE 125 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155 TABLE 126 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 156 10.4.4 AUSTRALIA 156 10.4.4.1 High prevalence of infectious diseases to fuel market 156 TABLE 127 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156 TABLE 128 AUSTRALIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157 TABLE 129 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 157 TABLE 130 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157 TABLE 131 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 158 10.4.5 REST OF ASIA PACIFIC 158 TABLE 132 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158 TABLE 133 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159 TABLE 134 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 159 TABLE 135 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159 TABLE 136 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 160 10.4.6 ASIA PACIFIC: RECESSION IMPACT 160 10.5 LATIN AMERICA 160 TABLE 137 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161 TABLE 138 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161 TABLE 139 LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161 TABLE 140 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 162 TABLE 141 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162 TABLE 142 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, ‘ 2021–2028 (USD MILLION) 162 10.5.1 BRAZIL 163 10.5.1.1 Improving healthcare infrastructure to support market growth 163 TABLE 143 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163 TABLE 144 BRAZIL: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163 TABLE 145 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 164 TABLE 146 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164 TABLE 147 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 164 10.5.2 MEXICO 165 10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth 165 TABLE 148 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 165 TABLE 149 MEXICO: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165 TABLE 150 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 166 TABLE 151 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166 TABLE 152 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 166 10.5.3 REST OF LATIN AMERICA 167 TABLE 153 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167 TABLE 154 REST OF LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167 TABLE 155 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 167 TABLE 156 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168 TABLE 157 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 168 10.5.4 LATIN AMERICA: RECESSION IMPACT 168 10.6 MIDDLE EAST & AFRICA 169 10.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 169 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 169 TABLE 158 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169 TABLE 159 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 170 TABLE 160 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 170 TABLE 161 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170 TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 171 11 COMPETITIVE LANDSCAPE 172 11.1 OVERVIEW 172 11.2 STRATEGIES ADOPTED BY KEY PLAYERS 173 11.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 174 FIGURE 39 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS 174 11.4 MARKET SHARE ANALYSIS 175 FIGURE 40 MOLECULAR QUALITY CONTROLS MARKET SHARE ANALYSIS, BY KEY PLAYER (2022) 175 TABLE 163 MOLECULAR QUALITY CONTROLS MARKET: INTENSITY OF COMPETITIVE RIVALRY 176 11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 177 11.5.1 STARS 177 11.5.2 EMERGING LEADERS 177 11.5.3 PERVASIVE PLAYERS 178 11.5.4 PARTICIPANTS 178 FIGURE 41 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 178 11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 179 11.6.1 PROGRESSIVE COMPANIES 179 11.6.2 STARTING BLOCKS 179 11.6.3 RESPONSIVE COMPANIES 179 11.6.4 DYNAMIC COMPANIES 179 FIGURE 42 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 180 11.7 COMPANY FOOTPRINT ANALYSIS 180 TABLE 164 MOLECULAR QUALITY CONTROLS MARKET: COMPANY FOOTPRINT ANALYSIS 181 TABLE 165 MOLECULAR QUALITY CONTROLS MARKET: ANALYTE TYPE FOOTPRINT ANALYSIS 182 TABLE 166 MOLECULAR QUALITY CONTROLS MARKET: APPLICATION FOOTPRINT ANALYSIS 183 TABLE 167 MOLECULAR QUALITY CONTROLS MARKET: REGIONAL FOOTPRINT ANALYSIS 184 TABLE 168 MOLECULAR QUALITY CONTROLS MARKET: END USER FOOTPRINT ANALYSIS 185 11.8 COMPETITIVE SITUATION AND TRENDS 186 11.8.1 PRODUCT LAUNCHES & APPROVALS 186 TABLE 169 PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023) 186 11.8.2 DEALS 187 TABLE 170 DEALS (JANUARY 2020–JUNE 2023) 187 11.8.3 OTHER DEVELOPMENTS 187 TABLE 171 OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023) 188 12 COMPANY PROFILES 189 12.1 KEY PLAYERS 189 (Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)* 12.1.1 LGC LIMITED 189 TABLE 172 LGC LIMITED: BUSINESS OVERVIEW 189 FIGURE 43 LCG LIMITED: COMPANY SNAPSHOT (2022) 190 12.1.2 THERMO FISHER SCIENTIFIC, INC. 198 TABLE 173 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 198 FIGURE 44 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 199 12.1.3 BIO-RAD LABORATORIES, INC. 205 TABLE 174 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 205 FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 206 12.1.4 MICROBIOLOGICS, INC. 209 TABLE 175 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 209 12.1.5 ABBOTT LABORATORIES 214 TABLE 176 ABBOTT LABORATORIES: BUSINESS OVERVIEW 214 FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 215 12.1.6 F. HOFFMANN-LA ROCHE LTD. 218 TABLE 177 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 218 FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 219 12.1.7 ZEPTOMETRIX, LLC 221 TABLE 178 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW 221 12.1.8 QUIDELORTHO CORPORATION 226 TABLE 179 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 226 FIGURE 48 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 227 12.1.9 QNOSTICS 229 TABLE 180 QNOSTICS: BUSINESS OVERVIEW 229 12.1.10 MAINE MOLECULAR QUALITY CONTROLS, INC. 232 TABLE 181 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW 232 12.1.11 RANDOX LABORATORIES LTD. 235 TABLE 182 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 235 12.1.12 DANAHER CORPORATION 238 TABLE 183 DANAHER CORPORATION: BUSINESS OVERVIEW 238 FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 239 12.1.13 BIO-TECHNE CORPORATION 241 TABLE 184 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 241 FIGURE 50 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 242 12.1.14 FORTRESS DIAGNOSTICS 244 TABLE 185 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW 244 12.1.15 MICROBIX BIOSYSTEMS 246 TABLE 186 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW 246 FIGURE 51 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2022) 247 12.1.16 GRIFOLS, S.A. 251 TABLE 187 GRIFOLS, S.A.: BUSINESS OVERVIEW 251 FIGURE 52 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022) 252 12.1.17 ANCHOR MOLECULAR 254 TABLE 188 ANCHOR MOLECULAR: BUSINESS OVERVIEW 254 12.1.18 SPEEDX PTY. LTD. 255 TABLE 189 SPEEDX PTY. LTD.: BUSINESS OVERVIEW 255 12.1.19 SEEGENE INC. 257 TABLE 190 SEEGENE INC.: BUSINESS OVERVIEW 257 FIGURE 53 SEEGENE INC: COMPANY SNAPSHOT (2022) 258 12.1.20 HELENA LABORATORIES CORPORATION 262 TABLE 191 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW 262 12.2 OTHER PLAYERS 265 12.2.1 SERO AS 265 TABLE 192 SERO AS: BUSINESS OVERVIEW 265 12.2.2 VIRCELL, S.L. 267 TABLE 193 VIRCELL, S.L.: BUSINESS OVERVIEW 267 12.2.3 STRECK LLC 269 TABLE 194 STRECK LLC.: BUSINESS OVERVIEW 269 12.2.4 SUN DIAGNOSTICS, LLC 271 TABLE 195 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW 271 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 272 TABLE 196 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW 272 *Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 13 APPENDIX 273 13.1 DISCUSSION GUIDE 273 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277 13.3 CUSTOMIZATION OPTIONS 279 13.4 RELATED REPORTS 279 13.5 AUTHOR DETAILS 280
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
MarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD(dna)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/08 10:26 154.13 円 166.76 円 202.76 円 |